文献速递核素与放射性配体治疗

PRRT治疗中剂量学参数的演变及其对临床实践的潜在影响:来自前瞻性II期LUMEN研究的数据

Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.
PubMed 文献 · EJNMMI Res · 2024-11-18

该研究分析37例胃肠胰神经内分泌肿瘤患者接受四周期[177Lu]Lu-DOTA-TATE治疗的前瞻性II期数据,每周期后行三时间点SPECT/CT剂量学评估。结果显示患者间吸收剂量变异大(肿瘤CoV约50%),胰腺NET肿瘤剂量随周期下降约13%/周期而肾脏上升约8%/周期,肿瘤有效半衰期胰腺NET短于肠道NET(77 h vs 107 h,p<0.0001)。

要点

  • 患者间肿瘤吸收剂量和活度浓度变异大,CoV约50%。
  • 胰腺NET肿瘤吸收剂量随周期下降约13%/周期,肾脏呈相反趋势约+8%/周期。
  • 肿瘤有效半衰期胰腺NET短于肠道NET(77 h vs 107 h,p<0.0001)。

核心结论

  • 接受标准化方案PRRT的NET患者中肿瘤吸收剂量存在相当大的变异。
  • 这些发现证实PRRT中需要考虑患者和肿瘤特征的个人化剂量学方法。

研究设计与样本

  • 分析前瞻性II期LuMEn研究入组的37例胰腺和肠道NET患者数据。
  • 治疗为四周期[177Lu]Lu-DOTA-TATE,周期间隔8-12周。
  • 每周期治疗后行三时间点SPECT/CT显像,按医学内照射剂量形式体系进行肿瘤和危及器官(肾脏和红骨髓)剂量学评估。
  • 采用变异系数评估吸收剂量、第1天活度浓度和有效半衰期的变异性,并用线性混合效应模型(SAS软件)分析剂量学参数随周期的演变,区分不同原发NET类型和肿瘤分级。

主要发现

  • 患者间吸收剂量和活度浓度变异大,尤其是肿瘤(CoV约50%)。
  • 胰腺NET中肿瘤吸收剂量和活度浓度随治疗周期下降,速率有限(约-13%/周期)。
  • 肾脏呈相反趋势(约+8%/周期)。
  • 危及器官和肿瘤的有效半衰期在各周期之间保持相对恒定。
  • 原发NET类型显著影响肿瘤有效半衰期,胰腺NET短于肠道NET(77 h vs 107 h,p<0.0001);未观察到分级对所研究变量的显著影响。

关键数值与推荐

  • 肿瘤吸收剂量和活度浓度的患者间CoV约50%。
  • 胰腺NET肿瘤吸收剂量和活度浓度约-13%/周期,肾脏约+8%/周期。
  • 肿瘤有效半衰期胰腺NET 77 h vs 肠道NET 107 h(p<0.0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE has emerged as a promising treatment for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Its treatment protocol is currently standardised for all patients, resulting in different patient outcomes. This study investigates the variability of tumours and organs-at-risk (kidneys and red marrow) dosimetric parameters across treatment cycles in patients with pancreatic and intestinal NETs. Data from 37 patients enrolled in a prospective phase II study (LuMEn) were analysed. Treatment consisted of four cycles of [177Lu]Lu-DOTA-TATE administered 8-12 weeks apart. Three-time-point SPECT/CT imaging was performed after each treatment cycle, and dosimetry of tumours and organs-at-risk (kidneys and red marrow) was conducted following the medical internal radiation dose formalism. Coefficients of variation (CoV) assessed the variability of absorbed doses, activity concentrations on day 1, and effective half-lives. Linear mixed effect models (SAS software) were used to investigate the evolution of the dosimetric parameters over cycles, discerning between different primary NET types and grades of tumours. RESULTS: There is an important variability in absorbed doses and activity concentrations among patients, particularly in tumours (CoV: ~50%). Tumour absorbed doses and activity concentrations decreased over treatment cycles in pancreatic NETs, although at a limited rate (~-13%/cycle). An opposite trend was observed for the kidneys ( ~ + 8%/cycle). Effective half-lives remained relatively constant across cycles for both organs-at-risk and tumours. The primary NET type significantly influenced effective half-lives in tumours, shorter in pancreatic NETs than intestinal NETs (77 h vs. 107 h, p < 0.0001). No significant effect of the grade was observed on either of the variables investigated. CONCLUSIONS: Our study revealed considerable variations in tumour absorbed doses among patients with NETs treated with a standardized protocol. These findings confirm the need for personalized dosimetry approaches in PRRT, considering patient and tumour characteristics. TRIAL REGISTRATION: EudraCT Number: 2012-003666-41. CLINICALTRIALS: gov identifier: NCT01842165. Registered 25 April 2013, https://clinicaltrials.gov/ct2/show/NCT01842165 .

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Danieli R, Mileva M, Marin G, et al. Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study. EJNMMI Res. 2024. PMID: 39557730. doi:10.1186/s13550-024-01163-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。